Vol 1, No 2 (2005)
Review paper
Published online: 2005-06-08

open access

Page views 700
Article views/downloads 2361
Get Citation

Connect on Social Media

Connect on Social Media

Prostate cancer chemotherapy

Maciej Krzakowski
Onkol. Prak. Klin 2005;1(2):72-75.

Abstract

Median survival of hormone-refractory prostate cancer patients is in a range of 10–12 months and a search for new options of systemic therapy is required. Until recently, the vast majority of cytotoxic agents provided low response rate and produced unsatisfactory palliation of symptoms. A new stage in prostate cancer chemotherapy is related to trials with the use of taxoids. Although these trials documented the superiority of docetaxel-based therapy, mitoxantrone combined with hydrocortisone remains standard therapeutic option, whereas the use of docetaxel should be limited to patients without cardiovascular comorbidities and risk factors for neurotoxicity.

Article available in PDF format

View PDF (Polish) Download PDF file